8-K 1 tm1924752-1_8k.htm FORM 8-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report

(Date of earliest event reported)

December 7, 2019

 

MARINUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36576   20-0198082

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

5 Radnor Corporate Center, Suite 500

100 Matsonford Rd, Radnor, PA

  19087
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code:  (484) 801-4670

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on
Which Registered
Common Stock, par value $0.001 per share   MRNS   Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 8.01.Other Events.

 

On December 7, 2019, Marinus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing additional data from a Phase 2 trial with ganaxolone in refractory status epilepticus to be presented at the American Epilepsy Society Annual Meeting. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and a copy of the slides that accompany this presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated by reference in this Item 8.01 as though fully set forth herein.

 

On December 9, 2019, the Company issued a press release announcing updates to its orphan seizure program including planned clinical program in tuberous sclerosis complex. A copy of the press release is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated by reference in this Item 8.01 as though fully set forth herein.

 

Item 9.01.Financial Statements and Exhibits.

 

Exhibit No.  Exhibit Description
    
99.1  Press Release dated December 7, 2019
    
99.2  Slide Presentation at American Epilepsy Society Annual Meeting on December 9, 2019 at 7:15 a.m. ET
    
99.3  Press Release dated December 9, 2019

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MARINUS PHARMACEUTICALS, INC.
   
   
  By: /s/ Edward Smith
    Edward Smith,
    Vice President, Chief Financial Officer,
    Secretary and Treasurer

 

Date:  December 9, 2019

 

3